A Biogen employee who has contracted Covid-19 in Massachusetts fled to Beijing alongside her family. And now she faces criminal charges for lying about her condition on the way back.

The company confirmed to Endpoints News that the woman, identified by Chinese officials as Ms. Li, works for the company but said she didn’t attend the strategy meeting in Boston that gave rise to a cluster of coronavirus cases.

“We believe Ms. Li is a U.S. based Biogen employee who made a personal decision to travel to China,” a spokesperson wrote in an email. “We are deeply dismayed by the situation as reported by the media in China.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

ARCH co-founder and managing director Bob Nelsen has a well known yen for the home run swing, betting big on potentially transformative meds and tech and the biotech teams he helps bring together. He thrives and bleeds on the cutting edge. And now Nelsen and the ARCH group have debuted 2 big funds to prove that this is the time for the best of biotech to shine — deadly pandemic be damned.

Two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, gathered a combined $1.46 billion. And that’s a record. ARCH Venture Fund IX and ARCH Venture Fund IX Overage closed in 2016 with a combined $1.1 billion. ARCH Venture Fund VIII and ARCH Venture Fund VIII Overage closed in 2014 with a combined $560 million.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Apart from disrupting biopharma R&D and regulatory timelines, the coronavirus pandemic has inevitably ravaged financial markets and eroded investor risk appetite. Investing in the time of coronavirus feels reckless, but if biotech venture funds are any indication, the time is ripe.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

You can now add Moderna CEO Stéphane Bancel to the list of biotech billionaires.

Since investors began to understand the full scope of the coronavirus outbreak in late February, cash has flushed out of much of the stock market and into the handful of companies leading the fight for drugs and vaccines. That’s meant hundreds of millions for Moderna, the Flagship-backed company that emerged early as the world’s first best hope for a Covid-19 vaccine.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Late last summer, one of the earliest stem cell therapy companies got two government decisions in the span of three weeks: The USPTO granted them a patent for iPSC-derived CAR-T cells, and then the FDA cleared them for their first-in-human CAR-NK trial.

Yesterday, the two technologies landed them an up-to $3.1 billion deal.

Fate Therapeutics and J&J announced a global collaboration that will pay Fate $100 million upfront and a trove of potential milestones to develop multiple CAR-T and CAR-NK therapies. It’s the first Big Pharma partnership Fate has announced in their 13-year existence and the largest, although at least one longtime follower thought they could have landed more.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

After providing an emergency approval to use malaria drugs against coronavirus with little actual evidence of their efficacy or safety in that setting, the FDA has already proven that it has set aside the gold standard when it comes to the pandemic. And now regulators have spelled out a new approach to speeding development that promises immediate responses in no uncertain terms — promising a program offering the ultimate high-speed pathway to Covid-19 drug approvals.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN